MINERALYS THERAPEUTICS, INC. Operating Income
MINERALYS THERAPEUTICS, INC. (MLYS) reported Operating Income of -$246.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$246.04M.
- MINERALYS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$45.34M.
- MINERALYS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$38.28M.
- MINERALYS THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$41.13M.
- MINERALYS THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$170.60M.
- MINERALYS THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$192.40M.
- MINERALYS THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$84.66M.
- MINERALYS THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$31.48M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$246.04M 10-Q · filed 2026-08-11 | -$291.38M 10-Q · filed 2026-08-11 | -$329.66M derived: sum of 3 quarters · filed 2026-08-11 | -$370.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$45.34M 10-Q · filed 2026-05-06 | -$83.62M derived: sum of 2 quarters · filed 2026-05-06 | -$124.75M derived: sum of 3 quarters · filed 2026-05-06 | -$171.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$38.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$79.41M derived: sum of 2 quarters · filed 2026-03-12 | -$126.16M derived: sum of 3 quarters · filed 2026-08-11 | -$170.60M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$41.13M 10-Q · filed 2025-11-10 | -$87.88M derived: sum of 2 quarters · filed 2026-08-11 | -$132.32M 10-Q · filed 2025-11-10 | -$184.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$46.75M 10-Q · filed 2026-08-11 | -$91.19M 10-Q · filed 2026-08-11 | -$142.96M derived: sum of 3 quarters · filed 2026-08-11 | -$203.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$44.45M 10-Q · filed 2026-05-06 | -$96.21M derived: sum of 2 quarters · filed 2026-05-06 | -$156.32M derived: sum of 3 quarters · filed 2026-05-06 | -$201.49M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$51.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$111.87M derived: sum of 2 quarters · filed 2026-03-12 | -$157.04M derived: sum of 3 quarters · filed 2026-03-12 | -$192.40M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$60.11M 10-Q · filed 2025-11-10 | -$105.27M derived: sum of 2 quarters · filed 2025-11-10 | -$140.64M 10-Q · filed 2025-11-10 | -$168.35M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$45.17M 10-Q · filed 2025-08-12 | -$80.53M 10-Q · filed 2025-08-12 | -$108.24M derived: sum of 3 quarters · filed 2025-08-12 | -$134.51M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$35.36M 10-Q · filed 2025-05-12 | -$63.07M derived: sum of 2 quarters · filed 2025-05-12 | -$89.35M derived: sum of 3 quarters · filed 2025-05-12 | -$105.08M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$27.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$53.98M derived: sum of 2 quarters · filed 2025-02-12 | -$69.72M derived: sum of 3 quarters · filed 2025-02-12 | -$84.66M 10-K · filed 2025-02-12 |
| 2023-09-30 | -$26.27M 10-Q · filed 2024-11-12 | -$42.01M derived: sum of 2 quarters · filed 2024-11-12 | -$56.95M 10-Q · filed 2024-11-12 | -$66.95M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$15.73M 10-Q · filed 2024-08-13 | -$30.67M 10-Q · filed 2024-08-13 | -$40.68M derived: sum of 3 quarters · filed 2024-08-13 | -$48.10M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$14.94M 10-Q · filed 2024-05-09 | -$24.95M derived: sum of 2 quarters · filed 2024-05-09 | -$32.37M derived: sum of 3 quarters · filed 2024-05-09 | -$38.85M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$10.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$17.43M derived: sum of 2 quarters · filed 2024-03-21 | -$23.91M derived: sum of 3 quarters · filed 2024-03-21 | -$31.48M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$7.42M 10-Q · filed 2023-11-07 | -$13.90M derived: sum of 2 quarters · filed 2023-11-07 | -$21.47M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$6.48M 10-Q · filed 2023-08-07 | -$14.05M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$7.57M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |